RALOXIFENE

Clinical Indication

Secondary prevention of osteoporotic fragility in menopausal women

Comments

In line with NICE TA 161

Date of classification

July 2018

Yellow

Specialist recommendation: Medicines initiated (and stabilised where appropriate) or recommended by a specialist service for prescribing in primary care. Requests should be clearly communicated either through written communication including using approved paperwork if available or verbal means as appropriate .